"Designing Growth Strategies is in our DNA"
The India plasma fractionation market was valued at USD 331.7 million in 2020. The market is projected to grow from USD 326.3 million in 2021 to USD 470.6 million by 2030, exhibiting a CAGR of 4.2% during the 2021-2030 period. The global impact of COVID-19 has been unprecedented and staggering, with plasma fractionation witnessing a positive impact on demand across all regions amid the pandemic. Based on our analysis, the India market exhibited an average growth of 3.6% in 2020 as compared to the average year-on-year growth during 2017-2019. The rise in CAGR is attributable to this market’s demand and growth, returning to pre-pandemic levels once the pandemic is over.
Blood consists of ~55% plasma, ~44% red blood cells, and <1% white blood cells and platelets. Blood plasma contains a wide variety of proteins such as immunoglobulins, albumin, and clotting factors. The downstream process used for the separation of plasma into its constituent proteins is known as plasma fractionation. Plasma can be obtained through whole blood as well as apheresis. However, commercial apheresis is not allowed in India. The collection of source plasma could be encouraged only as a voluntary activity in India. Plasma proteins can be used as therapies for people suffering from shock, burns, trauma, immune-deficiency disorders, and other medical conditions.
The market growth is attributed to the increasing number of patients suffering from shock, burns, and trauma. Moreover, a large patient pool affected by immune-deficiency disorders drives the market growth. Furthermore, rising focus of market players to increase their production capacities and the growing adoption of clotting factors to treat various types of hemophilia, such as Hemophilia A and Hemophilia B, boost the market.
COVID-19 Pandemic Boosted Market Revenue Due to Increased Adoption of Immunoglobulins
The COVID-19 pandemic positively impacted the market in 2020. Factors such as the surging number of patients suffering from COVID-19 and increasing adoption of antibodies in 2020, contributed positively to the market growth. The India plasma fractionation market growth witnessed a rate of 3.6% in 2020 as compared to 2.6% in 2019.
Additionally, in 2020, market players have focused on various strategies to meet the growing demand for antibodies. Several companies launched new products in the market to address the problem of the COVID-19 pandemic.
With the increase in demand for plasma-derived medicinal products, the market players have also increased their production capacities to fulfill the demand, resulting in high revenue compared to the historic years.
Request a Free sample to learn more about this report.
Strategic Initiatives to Boost Market Growth
The companies operating in the market constantly focus on strategies such as acquisitions, expansions, and mergers. These strategies help the companies increase their revenue, thereby fostering the overall market growth opportunities.
Moreover, many market players are involved in developing new plasma proteins for the treatment of various immune-deficiency disorders, which is expected to drive market growth in the coming years.
Rising Prevalence of Immune-deficiency Disorders to Drive Market Growth
Immune-deficiency disorders are a group of diseases that affect various arms of the immune system. X-linked agammaglobulinemia (XLA), common variable immunodeficiency (CVID), selective IgA deficiency with or without IgG2 subclass deficiency, isolated IgG2 subclass deficiency, and transient hypogammaglobulinemia of infancy are some of the most common immune-deficiency disorders in India.
The increasing number of people suffering from immune-deficiency disorders in India is expected to increase the adoption of plasma proteins thereby, fostering the overall market growth.
Increasing Demand for Coagulation Factors Due to High Burden of Hemophilia Strengthens Market Growth
Coagulation factors are the proteins in the plasma that help in the treatment of bleeding disorders. The extent of the clotting factor in the person’s blood decides the severity of hemophilia. The large number of patients suffering from hemophilia is expected to increase the demand for coagulation factors in the coming years.
With the rising number of hemophilia cases, the demand for coagulation factors is expected to increase during the forecast period. In India, the consumption of coagulation factors has increased over the past few years.
Thus, the rising coagulation factor VIII consumption and the growing prevalence of hemophilia A drive the market growth.
Low Availability of Domestic Plasma to Limit the Market Growth
With a high burden of chronic diseases in India, the shortage of blood and plasma creates a disturbance. The main factor contributing to India's blood shortage is deterioration during storage and expiry. Moreover, issues, such as contamination under donations, broken bags or seals, clotted donations, delays in conducting tests due to improper transport, and staff shortage, increase blood & plasma shortage and decrease the plasma available for fractionation.
The plasma for fractionation is very low due to such high blood wastage. Moreover, the increasing use of plasma for clinical applications reduces the amount of plasma available for fractionation.
To know how our report can help streamline your business, Speak to Analyst
Immunoglobulin Segment to Hold a Major Share of the India Market During 2021-2030
Based on product, the India plasma fractionation market is segmented into albumin, immunoglobulin, coagulation factors, and others.
The immunoglobulins segment held the highest market share in 2020 and is anticipated to expand at the fastest CAGR during the forecast period. The large share of the immunoglobulins segment is attributed to the increasing incidence of autoimmune, idiopathic, and infectious disorders and the rising focus of market players to launch immunoglobulins in the coming years.
The albumin segment is projected to expand at a substantial CAGR during the forecast period. Factors, such as increasing number of surgical procedures, rising prevalence of burns, and increasing use of albumin for the treatment of shock and other severe infections, are expected to contribute to the segmental growth.
Immunology & Neurology Segment to Dominate the Market During the Forecast Period
Based on application, the market is segmented into immunology & neurology, hematology, critical care, pulmonology, and others.
The immunology & neurology segment accounted for the largest market share in 2020 and is expected to expand at a significant CAGR during the forecast period. The growing prevalence of primary immunodeficiency disorders and the rising demand for immunoglobulins for various medical conditions drive the segmental growth.
The hematology segment is anticipated to expand at a substantial CAGR during the forecast period, 2021-2030. The segmental growth is attributed to the increasing number of patients suffering from bleeding disorders and rising use of Coagulation Factor VIII and Factor IX in India.
Hospitals & Clinics Segment to Continue Dominance During the Forecast Period
Based on end-user, the market is segmented into hospitals & clinics, research organizations, and others.
In 2020, the hospitals & clinics segment held the highest market share and is expected to expand at the highest CAGR during the forecast timeframe, 2021-2030. This segment's large share and high growth rate are attributed to the increasing number of surgical procedures in hospitals, high flow of patients suffering from immune-deficiency disorders in hospitals & clinics, growing use of albumin in hospitals for burns, and rising number of hospitals & clinics in India.
Companies with the Fractionation Plants/Centers to Hold Key Market Share
The India market is highly consolidated due to the presence of limited players offering plasma proteins in India. Key players, such as Reliance Life Sciences, Intas Pharmaceuticals Ltd, Hemarus, and VIRCHOW BIOTECH, accounted for the majority of the market share in 2020.
Reliance Life Sciences dominated the market in 2020. The company has the oldest in-house plasma fractionation unit, which is one of the key factors contributing to its dominance in India. Moreover, factors, such as better capabilities in research & development, manufacturing, process development, and marketing, strengthen its market share in India.
Other companies, such as PlasmaGen BioSciences Pvt. Ltd., Bharat Serums and Vaccines Limited (BSV), Biocon Limited, and Fusion Healthcare, held substantial market shares due to their strong presence in India. Furthermore, strategic initiatives such as production capacity expansion and new product launches are expected to increase their market shares in the long run.
An Infographic Representation of India Plasma Fractionation Market
To get information on various segments, share your queries with us
The India plasma fractionation market research report provides a detailed analysis of the industry. It focuses on key aspects such as leading companies, types of plasma proteins, and product applications. Besides this, it offers insights into the market trends and highlights key industry developments. In addition to the factors mentioned above, the report includes insights related to plasma fractionation regulations, production capacity, future strategies of the market players, investment initiatives, self-sufficiency of plasma-derived medicinal products (PDMPs), and supply chain analysis.
Value (USD Million)
Fortune Business Insights says that the market stood at USD 331.7 million in 2020 and is projected to reach USD 470.6 million by 2030.
The market is expected to exhibit steady growth at a CAGR of 4.2% during the forecast period (2021-2030).
By product, the immunoglobulins segment is set to lead the market.
The rising prevalence of immune-deficiency disorders, growing geriatric population, increasing number of patients suffering from hemophilia, and a strong focus of market players toward the manufacturing capacity expansions are some of the key factors driving the market.
Reliance Life Science, Intas Pharmaceuticals Ltd, Hemarus, and VIRCHOW BIOTECH are the top players in the market.
“We are happy with the professionalism of your in-house research team as well as the quality of your research reports. Looking forward to work together on similar projects”- One of the Leading Food Companies in Germany
“We appreciate the teamwork and efficiency for such an exhaustive and comprehensive report. The data offered to us was exactly what we were looking for. Thank you!”- Intuitive Surgical
“I recommend Fortune Business Insights for their honesty and flexibility. Not only that they were very responsive and dealt with all my questions very quickly but they also responded honestly and flexibly to the detailed requests from us in preparing the research report. We value them as a research company worthy of building long-term relationships.”- Major Food Company in Japan
“Well done Fortune Business Insights! The report covered all the points and was very detailed. Looking forward to work together in the future”- Ziering Medical
“It has been a delightful experience working with you guys. Thank you Fortune Business Insights for your efforts and prompt response”- Major Manufacturer of Precision Machine Parts in India
“I had a great experience working with Fortune Business Insights. The report was very accurate and as per my requirements. Very satisfied with the overall report as it has helped me to build strategies for my business”- Hewlett-Packard
“This is regarding the recent report I bought from Fortune Business insights. Remarkable job and great efforts by your research team. I would also like to thank the back end team for offering a continuous support and stitching together a report that is so comprehensive and exhaustive”- Global Management Consulting Firm
“Please pass on our sincere thanks to the whole team at Fortune Business Insights. This is a very good piece of work and will be very helpful to us going forward. We know where we will be getting business intelligence from in the future.”- UK-based Start-up in the Medical Devices Sector
“Thank you for sending the market report and data. It looks quite comprehensive and the data is exactly what I was looking for. I appreciate the timeliness and responsiveness of you and your team.”- One of the Largest Companies in the Defence Industry